Major investments in life science capabilities and Swedish healthcare have been made during recent years and more will follow. Cutting edge research infrastructure are already largely in place. New Karolinska Solna, part of a multi-billion Euro investment in infrastructure, will be inaugurated in the autumn of 2016. AstraZeneca will build a new 225 million Euro manufacturing facility for biologics and GE Healthcare have announced a 90 million Euro investments in their protein purification production. The government, a private foundation and AstraZeneca will jointly invest in biologics and a number of other initiatives across the country are under way.
The Swedish government has made major investments in the country’s life sciences research infrastructure with the aim to enable cutting edge research and development of life science solutions.
In anticipation of continued growth in biologics, two global giants, AstraZeneca and GE Healthcare have chosen Sweden for their next investments in capacities for protein-based pharmaceuticals.
Sweden aims at strengthening its existing competitive edge in protein science further through two new initiatives, one is a consortium between the Swedish government, AstraZeneca and Sweden’s leading, private, research funding body the Knut and Alice Wallenberg Foundation. The second is a government funded program focusing on biologics.